MEMORIAL SLOAN-KETTERING CANCER CENTER;AGENUS INC.;LUDWIG INSTITUTE FOR CANCER RESEARCH LTD.
发明人:
WILSON, Nicholas S.,WAIGHT, Jeremy D.,RITTER, Gerd,SCHAER, David,HIRSCHHORN-CYMERMAN, Daniel,MERGHOUB, Taha,BREOUS-NYSTROM, Ekaterina V.,SEIBERT, Volker,TSUJI, Takemasa,LEGER, Olivier,UNDERWOOD, Denni
申请号：
SG11201804265X
公开号：
SG11201804265XA
申请日:
2016.12.02
申请国别(地区):
SG
年份:
2018
代理人:
摘要：
The present disclosure provides multispecific (e.g., bispecific) antibodies that specifically bind to human GITR and/or human OX40 as well as compositions comprising such antibodies. In a specific aspect, the multispecific antibodies specifically bind to human GITR and OX40 and modulate GITR and/or OX40 activity, e.g., enhance, activate, or induce GITR and/or OX40 activity, or reduce, deactivate, or inhibit GITR and/or OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., enhances, activates, or induces GITR and/or OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., reduces, deactivates, or inhibits GITR and/or OX40 activity.
